Component

Silicon preparation containing 75% orthosilicic acid

Context-specific entity; species, compartment and exposure are stated on each claim.

7 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. The silicon preparation lowered Tartrate-resistant acid phosphatase mRNA at 48 and 72 hours.

    Silicon preparation containing 75% orthosilicic acid → Human Tartrate-resistant acid phosphatase source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL.
    limitations
    Transcript abundance is not direct inhibition of the protein.
    nutrient_topic
    Silica collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Silica and soluble silicon
    plain_language
    A specific osteoclast marker changed during differentiation.
    primary_references
    Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169

    Silica: soluble silicon, cellular transport and particle-specific mechanisms (2026-09-19) · lines 232–238

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL. · source_derived_draft · unverified_draft

    ## silica-osteoclast-acp5 A specific osteoclast marker changed during differentiation. The silicon preparation lowered Tartrate-resistant acid phosphatase mRNA at 48 and 72 hours. Model: Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL. Limitations: Transcript abundance is not direct inhibition of the protein. Evidence access: Primary full text Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169
    Complete structured claim and evidence

  2. AQP9 mRNA increased significantly at 72 hours during silicon exposure.

    Silicon preparation containing 75% orthosilicic acid → Human aquaporin 9 / AQP9 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human CD14+ osteoclast cultures.
    limitations
    No AQP9 loss-of-function test demonstrated that it mediated the resorption effect.
    nutrient_topic
    Silica collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Silica and soluble silicon
    plain_language
    Transporter expression changed even while differentiation markers fell.
    primary_references
    Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169

    Silica: soluble silicon, cellular transport and particle-specific mechanisms (2026-09-19) · lines 256–262

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human CD14+ osteoclast cultures. · source_derived_draft · unverified_draft

    ## silica-osteoclast-aqp9 Transporter expression changed even while differentiation markers fell. AQP9 mRNA increased significantly at 72 hours during silicon exposure. Model: Human CD14+ osteoclast cultures. Limitations: No AQP9 loss-of-function test demonstrated that it mediated the resorption effect. Evidence access: Primary full text Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169
    Complete structured claim and evidence

  3. The silicon preparation lowered Calcitonin receptor mRNA at 48 hours.

    Silicon preparation containing 75% orthosilicic acid → Human Calcitonin receptor source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL.
    limitations
    Transcript abundance is not direct inhibition of the protein.
    nutrient_topic
    Silica collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Silica and soluble silicon
    plain_language
    A specific osteoclast marker changed during differentiation.
    primary_references
    Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169

    Silica: soluble silicon, cellular transport and particle-specific mechanisms (2026-09-19) · lines 240–246

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL. · source_derived_draft · unverified_draft

    ## silica-osteoclast-calcr A specific osteoclast marker changed during differentiation. The silicon preparation lowered Calcitonin receptor mRNA at 48 hours. Model: Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL. Limitations: Transcript abundance is not direct inhibition of the protein. Evidence access: Primary full text Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169
    Complete structured claim and evidence

  4. The silicon preparation lowered Cathepsin K mRNA at 48 and 72 hours.

    Silicon preparation containing 75% orthosilicic acid → Human Cathepsin K source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL.
    limitations
    Transcript abundance is not direct inhibition of the protein.
    nutrient_topic
    Silica collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Silica and soluble silicon
    plain_language
    A specific osteoclast marker changed during differentiation.
    primary_references
    Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169

    Silica: soluble silicon, cellular transport and particle-specific mechanisms (2026-09-19) · lines 224–230

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL. · source_derived_draft · unverified_draft

    ## silica-osteoclast-ctsk A specific osteoclast marker changed during differentiation. The silicon preparation lowered Cathepsin K mRNA at 48 and 72 hours. Model: Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL. Limitations: Transcript abundance is not direct inhibition of the protein. Evidence access: Primary full text Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169
    Complete structured claim and evidence

  5. The silicon preparation lowered DC-STAMP mRNA at 48 and 96 hours.

    Silicon preparation containing 75% orthosilicic acid → Human DC-STAMP source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL.
    limitations
    Transcript abundance is not direct inhibition of the protein.
    nutrient_topic
    Silica collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Silica and soluble silicon
    plain_language
    A specific osteoclast marker changed during differentiation.
    primary_references
    Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169

    Silica: soluble silicon, cellular transport and particle-specific mechanisms (2026-09-19) · lines 248–254

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL. · source_derived_draft · unverified_draft

    ## silica-osteoclast-dcstamp A specific osteoclast marker changed during differentiation. The silicon preparation lowered DC-STAMP mRNA at 48 and 96 hours. Model: Human RANKL-stimulated CD14+ cultures, 50 micrograms Si/mL. Limitations: Transcript abundance is not direct inhibition of the protein. Evidence access: Primary full text Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169
    Complete structured claim and evidence

  6. The 75%-OSA silicon preparation reduced RANKL-stimulated TRAP-positive multinucleated human osteoclasts.

    Silicon preparation containing 75% orthosilicic acid → Human osteoclast differentiation under silicon exposure source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human CD14+ monocytes, M-CSF and recombinant mouse RANKL; 50 micrograms Si/mL.
    limitations
    About 1.8 mM total Si, not a normal plasma exposure or chemically pure OSA.
    nutrient_topic
    Silica collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Silica and soluble silicon
    plain_language
    Fewer bone-resorbing cells formed under these culture conditions.
    primary_references
    Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169

    Silica: soluble silicon, cellular transport and particle-specific mechanisms (2026-09-19) · lines 216–222

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human CD14+ monocytes, M-CSF and recombinant mouse RANKL; 50 micrograms Si/mL. · source_derived_draft · unverified_draft

    ## silica-osteoclast-differentiation Fewer bone-resorbing cells formed under these culture conditions. The 75%-OSA silicon preparation reduced RANKL-stimulated TRAP-positive multinucleated human osteoclasts. Model: Human CD14+ monocytes, M-CSF and recombinant mouse RANKL; 50 micrograms Si/mL. Limitations: About 1.8 mM total Si, not a normal plasma exposure or chemically pure OSA. Evidence access: Primary full text Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169
    Complete structured claim and evidence

  7. Silicon treatment reduced resorption pits and released type I collagen fragments on bone slices.

    Silicon preparation containing 75% orthosilicic acid → Human osteoclast bone resorption source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human osteoclast bone-disc assays; 50 micrograms Si/mL.
    limitations
    Not demonstrated clinical fracture prevention.
    nutrient_topic
    Silica collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Silica and soluble silicon
    plain_language
    The study measured matrix breakdown as well as cell markers.
    primary_references
    Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169

    Silica: soluble silicon, cellular transport and particle-specific mechanisms (2026-09-19) · lines 264–270

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human osteoclast bone-disc assays; 50 micrograms Si/mL. · source_derived_draft · unverified_draft

    ## silica-osteoclast-resorption The study measured matrix breakdown as well as cell markers. Silicon treatment reduced resorption pits and released type I collagen fragments on bone slices. Model: Human osteoclast bone-disc assays; 50 micrograms Si/mL. Limitations: Not demonstrated clinical fracture prevention. Evidence access: Primary full text Orthosilicic acid inhibits human osteoclast differentiation and bone resorption. · 2024 · https://pubmed.ncbi.nlm.nih.gov/39405281/ · DOI 10.1371/journal.pone.0312169
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards